Eli Lilly (LLY)
(Delayed Data from NYSE)
$915.04 USD
+10.07 (1.11%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $911.40 -3.64 (-0.40%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LLY 915.04 +10.07(1.11%)
Will LLY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Tap the Weight-Loss Drug Market With These ETFs
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Other News for LLY
Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
American Century Growth Fund Q2 2024 Commentary
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Vanda slips as FDA rejects therapy for stomach condition